A hematocrit above the normal range signals that your blood contains a higher-than-expected proportion of red blood cells, and the consequences range from trivially fixable to life-threatening depending on the cause. For most labs, “high” means above roughly 48–49% in men and 44–48% in women, though thresholds vary slightly. The immediate concern is that thicker blood flows less easily, raising the risk of clots, stroke, and heart problems. But the real question your doctor needs to answer is why it is high, because a dehydrated marathon runner and a patient with a bone-marrow cancer can both show the same elevated number on a blood draw, yet they need very different responses.
Why Thicker Blood Is a Problem
Red blood cells carry oxygen, so you might assume that more of them is simply better. Up to a point, that is true: your body routinely adjusts red cell production to meet oxygen demand. But once hematocrit climbs too high, the physical properties of blood start working against you. Blood viscosity rises, and sludgier blood puts more stress on vessel walls and the heart.
The relationship between viscosity and blood flow is not entirely straightforward. Higher viscosity does increase vascular resistance, but it also raises the shear stress on blood-vessel linings, which stimulates those cells to produce nitric oxide, a molecule that relaxes blood vessels and promotes dilation.1PubMed Central. Blood Rheology: Key Parameters, Impact on Blood Flow, Role in Sickle Cell Disease and Effects of Exercise That built-in brake helps protect you to a degree, but it has limits. Once hematocrit stays persistently elevated, the compensatory vasodilation is overwhelmed, and the clotting risk becomes real.
Large population studies bear this out. In one prospective study of over 26,000 adults, every five-percentage-point rise in hematocrit was associated with roughly a 25% increase in the risk of venous thromboembolism after adjusting for age, weight, and smoking. Men whose hematocrit sat in the top fifth of the range had about two-and-a-half times the risk of an unprovoked clot compared to those in the lower portion.2PubMed Central. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study Other research has found that higher hematocrit is independently linked to ischemic heart disease and stroke as well, reinforcing a consistent dose-response pattern: the higher the hematocrit, the greater the vascular danger.3PubMed Central. Hematocrit and the incidence of stroke: a prospective, population-based cohort study
Polycythemia Vera and the Bone Marrow
The most serious cause of a persistently high hematocrit is polycythemia vera (PV), a slow-growing blood cancer in which the bone marrow churns out far too many red blood cells on its own, regardless of how much oxygen the body actually needs. PV is driven almost entirely by a single genetic mutation in the JAK2 gene. The best-known variant, called V617F, shows up in close to 97% of cases and essentially jams the growth-signaling switch for red blood cell precursors in the “on” position.4memo – Magazine of European Medical Oncology. JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications
Beyond flooding the bloodstream with extra red cells, the JAK2 mutation also ramps up inflammatory signaling. Elevated levels of various pro-inflammatory molecules contribute to disease progression, encouraging further cell growth and suppressing normal cell death.5Asian Journal of Dairy and Food Research. Interplaying Correlation of Some Genetic and Inflammatory Factors among Patients with Polycythemia Vera This inflammatory backdrop helps explain why PV patients often feel lousy in ways that go beyond what a simple red-cell count would predict: fatigue, night sweats, and bone pain are all common. It also explains why treatment needs to address more than just the hematocrit number itself.
Secondary Polycythemia From Low Oxygen
If the bone marrow is healthy but the body senses that tissues are not getting enough oxygen, it responds by making more red blood cells. This is secondary polycythemia, and it accounts for a large share of the elevated hematocrit readings doctors encounter in everyday practice.
The mechanism works through the kidneys. When oxygen-depleted blood passes through them, they secrete erythropoietin (EPO), which travels to the bone marrow and orders an increase in red cell production. In the short term this is a perfectly healthy adaptation. Over months or years, though, chronic hypoxia pushes EPO production into overdrive and the resulting excess of red cells thickens the blood enough to cause clotting problems.6PubMed Central. Secondary polythaemia from chronic hypoxia is a risk for cerebral thrombosis: a case report
Chronic hypoxia is the single most common trigger for secondary polycythemia. The usual suspects include chronic obstructive pulmonary disease (COPD), interstitial lung disease, obstructive sleep apnea, and prolonged high-altitude living, all of which keep blood oxygen levels persistently low and stimulate ongoing EPO production.7PubMed Central. Secondary polycythemia as a rare cause of ischemic stroke: A case report Heavy smoking can compound any of these because carbon monoxide in cigarette smoke binds to hemoglobin and reduces the blood’s oxygen-carrying capacity, nudging the body toward producing even more red cells. Research on sleep apnea patients has confirmed that overnight oxygen saturation, age, and pack-years of smoking all independently predict hematocrit level.8PubMed. Hematocrit levels in sleep apnea
Tumors That Make Their Own EPO
A less common but clinically important cause of secondary polycythemia is EPO production by a tumor. Certain cancers, particularly kidney cancers, can manufacture erythropoietin on their own, flooding the bloodstream and driving red cell counts up independently of any oxygen shortage. About one to five percent of renal cell carcinomas are associated with polycythemia through this mechanism.9PubMed. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia Research has confirmed that it is the malignant cells themselves, not the surrounding tissue, that produce the hormone.10Blood. Tumor Cells Are the Site of Erythropoietin Synthesis in Human Renal Cancers Associated With Polycythemia
Other tumors occasionally linked to ectopic EPO production include liver cancers (hepatocellular carcinoma), uterine fibroids, and certain brain tumors. In these cases, the high hematocrit is actually a useful diagnostic clue that something is growing where it should not be. Treating or removing the tumor typically brings the red cell count back to normal without any direct blood therapy.
Medications and Exogenous Substances
A growing number of prescription drugs can push hematocrit upward, and this is worth knowing because it means your lab result may not signal a disease at all. Testosterone replacement therapy is the most common culprit: testosterone stimulates red blood cell production directly, and elevated hematocrit is one of the most frequently monitored side effects in men receiving it. SGLT-2 inhibitors, a widely prescribed class of diabetes drugs, have also been shown to stimulate red blood cell production.11PubMed. Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy Taken together, as some men with type 2 diabetes do, the combination carries a higher erythrocytosis risk than either drug alone.
Anabolic steroids used without medical supervision work through essentially the same pathway as prescribed testosterone but at higher and less predictable doses, making hematocrit spikes more severe. EPO itself is sometimes abused in endurance sports to boost oxygen-carrying capacity, and it predictably raises hematocrit to dangerous levels. If you are taking any of these substances, your doctor will want to monitor your blood counts more frequently.
Relative Polycythemia and Dehydration
Not every high hematocrit reading means you have too many red blood cells. Sometimes the red cell count is perfectly normal but the liquid part of the blood (plasma) has shrunk, making the ratio look abnormally high. This is called relative polycythemia, and its most common cause is dehydration. A bout of vomiting, heavy sweating during exercise, or simply not drinking enough water can temporarily concentrate the blood enough to trigger an abnormal reading.
A condition called Gaisböck syndrome describes chronic apparent polycythemia in people (typically middle-aged, overweight men with high blood pressure) who consistently show elevated hematocrit without a true increase in red cell mass. The first step in any diagnostic workup for high hematocrit is determining whether the elevation is real or relative, because the treatment for dehydration is a glass of water, not a medical procedure.12PubMed Central. JAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches
Symptoms That Suggest Your Hematocrit Is Too High
Mild elevations often produce no symptoms at all and are caught incidentally on routine bloodwork. As hematocrit climbs higher, you may notice headaches, dizziness, blurred vision, or a flushed or ruddy complexion. Fatigue is paradoxically common: even though you have more oxygen carriers than usual, the blood is too thick to deliver its cargo efficiently.
One of the most distinctive symptoms tied to polycythemia vera is aquagenic pruritus, a severe itching that flares after contact with water, especially warm water like a bath or shower. In a study of 441 PV patients, about two-thirds experienced this itching, and in most of them it appeared on average nearly three years before they were diagnosed with PV. For roughly 15% of those affected, the itch was classified as “unbearable,” and it correlated with lower self-reported quality of life, more fatigue, and more pain.13PubMed Central. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice If you develop unexplained itching after bathing, it is worth asking your doctor to check a complete blood count.
Certain rare forms of erythrocytosis carry particularly high clotting risk even at relatively modest hematocrit elevations. Chuvash erythrocytosis, a hereditary condition caused by mutations in the oxygen-sensing pathway, is associated with high rates of both arterial and venous clots in affected individuals living near sea level.14Haematologica. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis This underscores that the cause of a high hematocrit matters as much as the number itself when assessing risk.
How Doctors Track Down the Cause
The diagnostic workup follows a logical sequence. After confirming the hematocrit is genuinely elevated on repeat testing (and ruling out dehydration), the most clinically important next step is screening for the JAK2 mutation to rule polycythemia vera in or out. If that test is negative, the investigation branches based on the EPO level in your blood. A low EPO suggests the bone marrow is acting on its own, pointing toward a primary marrow disorder or a rare hereditary condition like an EPO-receptor mutation. A high EPO suggests something is driving the marrow from outside, whether that is chronic low oxygen, a tumor making its own EPO, or a medication effect.12PubMed Central. JAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches
Your doctor will also want to know whether the elevation is new or has been present for years. Lifelong erythrocytosis with a positive family history points toward hereditary causes, while a recent change is more suggestive of an acquired condition like PV or a new medication. Oxygen-saturation testing, lung-function studies, and imaging of the kidneys and abdomen may all be part of the workup depending on which direction the initial results point.
Phlebotomy as First-Line Treatment
For most causes of genuinely elevated hematocrit, the fastest way to bring the number down is phlebotomy: removing a unit of blood, just like donating at a blood bank. This immediately reduces the red cell concentration and lowers viscosity. In PV patients, the standard target is to keep hematocrit at or below 45%, a threshold associated with lower thrombotic risk.15PubMed. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial
Research on phlebotomy intervals suggests that sessions spaced less than two weeks apart are most effective at bringing hematocrit down to target, while sessions every three to four weeks are sufficient to maintain it once the goal has been reached. None of the patients in that study experienced a thrombotic event after starting regular phlebotomy, regardless of whether they were also taking medication.16Korean Journal of Blood Transfusion. Optimal Phlebotomy Interval to Change Hematocrit Levels in Patients with Polycythemia The procedure is simple and safe, though repeated sessions can eventually cause iron deficiency, which is actually a partly desirable side effect since low iron stores slow down new red cell production.
Medications for Polycythemia Vera
When phlebotomy alone is not enough to keep hematocrit controlled, or when PV patients are at high risk for clotting (older age, prior clot, very high white cell or platelet counts), doctors add cytoreductive therapy, meaning medication that dials back the bone marrow’s overproduction. Hydroxyurea is the standard first-line drug and has been used for decades. It works broadly to slow cell division in the marrow, bringing down red cells, white cells, and platelets together.
For patients who do not respond well to hydroxyurea or cannot tolerate it, ruxolitinib is an approved second-line option. It directly targets the JAK signaling pathway that the mutant JAK2 gene has hijacked.13PubMed Central. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice In a randomized trial comparing ruxolitinib to standard therapy (mostly continued hydroxyurea), 60% of ruxolitinib patients achieved hematocrit control compared to 20% on standard therapy, and the drug also shrank enlarged spleens far more effectively.17PubMed Central. Ruxolitinib versus standard therapy for the treatment of polycythemia vera Beyond hematocrit numbers, ruxolitinib offers significant relief from the constitutional symptoms that make PV miserable day to day, including the aquagenic pruritus discussed earlier.
Low-Dose Aspirin and Clot Prevention
Alongside hematocrit-lowering strategies, low-dose aspirin plays a supporting role in PV management. Platelets in PV patients produce excess thromboxane A2, a molecule that promotes clot formation, and aspirin suppresses this.15PubMed. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial A large randomized trial found that low-dose aspirin cut the combined risk of heart attack, stroke, pulmonary embolism, and major venous clots by about 60% compared to placebo, without a significant increase in major bleeding.18PubMed. Efficacy and safety of low-dose aspirin in polycythemia vera This is now standard care for essentially all PV patients unless they have a specific contraindication to aspirin.
When Babies Are Born With High Hematocrit
Newborns are a special case. Neonatal polycythemia, defined as a hematocrit above 65%, is relatively common and usually a consequence of delayed cord clamping, twin-to-twin transfusion, or maternal diabetes. Most affected newborns are asymptomatic and do fine without intervention. For symptomatic babies, a procedure called partial exchange transfusion has been used to dilute the blood, but research has failed to show clear long-term neurodevelopmental benefits from treating asymptomatic neonates this way.19PubMed. Neonatal polycythemia and hyperviscosity Current practice leans toward watchful waiting unless the baby shows clear symptoms like sluggish feeding, breathing difficulty, or seizures.
The Iron Deficiency Paradox
Here is something that can puzzle patients and even trip up clinicians: it is possible to have too many red blood cells and iron deficiency at the same time. When this happens, the red cells are abnormally small (microcytic) but abnormally numerous, so the overall hematocrit may still read as elevated. The classic causes of this combination are an inherited hemoglobin trait called thalassemia minor, or polycythemia vera that has been treated with enough phlebotomy to deplete iron stores.20PubMed. Microcytic polycythemia. Frequency of nonthalassemic causes
This matters in practice because a doctor seeing small red cells on a blood smear might reflexively think iron deficiency or thalassemia and miss the underlying polycythemia, especially if the hemoglobin level has been dragged into the normal range by the iron depletion. If your blood count shows a paradoxical combination of high red cell numbers and low red cell size, a more thorough workup is warranted to distinguish between these possibilities.